TACALYX
Tacalyx, a spin-off from Max-Planck-Institute of Colloids and Interfaces, Potsdam/Germany (MPICI), focuses on Tumor-Associated Carbohydrate Antigens (TACAs) as novel target class for cancer treatment. The highly tumor-specific expression of TACAs results from aberrant glycosylation and promotes metastasis, angiogenesis and suppression of the immune system. Tacalyx uses the sophisticated technology of carbohydrate synthesis to synthesize highly pure TACA structures for the generation and identification of antibodies that will be developed into novel therapeutics for the treatment of cancer.
TACALYX
Industry:
Biotechnology Health Care Life Science Therapeutics
Founded:
2019-01-01
Address:
Berlin, Berlin, Germany
Country:
Germany
Website Url:
http://www.tacalyx.com
Total Employee:
1+
Status:
Active
Contact:
+49 30 407 237 10
Total Funding:
14 M EUR
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro SPF Google Font API Google Maps SSL By Default IPv6 Apache Microsoft Exchange Online
Similar Organizations
1859
1859 is a biotechnology company focusing on the discovery and development of next-generation therapeutics.
Allinky Biopharma
Allinky Biopharma is a company dedicated to the discovery and development of novel therapeutic agents
AlveoGene
AlveoGene is an innovative company focused on transforming rare respiratory disease outcomes using inhaled gene therapy.
Apeiron Biologics
Apeiron Biologics is a biotech company that focuses on the discovery and development of novel cancer immunotherapies.
D2M Biotherapeutics
D2M Biotherapeutics focuses on the development of novel immunotherapeutics.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
RNAimmune
RNAimmune is a biopharmaceutical company specializing in the discovery and development of mRNA-based therapeutics and vaccines.
Current Advisors List
Board_member
Board_member
Board_member
Board_member
2019-07-01
Board_member
Board_member
Board_member
Current Employees Featured
Peter Sondermann CEO @ Tacalyx
CEO
2019-07-01
Founder
Investors List
Thuja Capital
Thuja Capital investment in Seed Round - Tacalyx
Kurma Partners
Kurma Partners investment in Seed Round - Tacalyx
Creathor Ventures
Creathor Ventures investment in Seed Round - Tacalyx
coparion
coparion investment in Seed Round - Tacalyx
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund investment in Seed Round - Tacalyx
Idinvest Partners
Idinvest Partners investment in Seed Round - Tacalyx
HTGF | High-Tech Gruenderfonds
HTGF | High-Tech Gruenderfonds investment in Seed Round - Tacalyx
Official Site Inspections
http://www.tacalyx.com Semrush global rank: 14.08 M Semrush visits lastest month: 60
- Host name: 217-160-0-104.elastic-ssl.ui-r.com
- IP address: 217.160.0.104
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
More informations about "Tacalyx"
Home – Tacalyx GmbH
Tacalyx was founded in 2019 as a spin-out of the Max-Planck-Institute of Colloids and Interfaces (MPICI) in Potsdam, Germany, with the help of Prof. Dr. Peter Seeberger and Dr. Oren …See details»
Tacalyx - Crunchbase Company Profile & Funding
Organization. Tacalyx . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... Tacalyx uses the …See details»
TACALYX GmbH Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for TACALYX GmbH of Berlin, Berlin. Get the latest business insights from Dun & Bradstreet.See details»
Tacalyx - Products, Competitors, Financials, Employees, …
Tacalyx is developing a pipeline of antibody-based therapies targeting TACAs (tumour-associated carbohydrate antigens), for the treatment of solid tumours. “We see great potential with the …See details»
Tacalyx - Funding, Financials, Valuation & Investors - Crunchbase
Tacalyx is a biotech company focused on the discovery and development of novel anti-TACA. New. Resources. Advanced Search. Start Free Trial . Talk With Sales. Pricing. Log In. Log In. …See details»
Tacalyx Company Profile - Office Locations, Competitors ... - Craft
Tacalyx is a biotech company that focuses on the discovery and development of novel anti-TACA (tumor-associated carbohydrate antigens) cancer therapies. The company develops …See details»
Tacalyx 2025 Company Profile: Valuation, Funding
Tacalyx General Information Description. Developer of therapeutics designed to target cancer-specific carbohydrate antigens. The company's therapeutics combine the ability to synthesize sufficient amounts of complex structures with …See details»
Tacalyx - Startbase
DGAP-News - Tacalyx ernennt Dr. Klaus Schollmeier zum Vorsitzenden des Aufsichtsrats 05.11.2020 - DGAP-News: Tacalyx GmbH / Schlagwort(e): Personalie Tacalyx ernennt Dr. Klaus Schollmeier zum Vorsitzenden des …See details»
Senior Scientist/Group Leader (m/f/d) Antibody and Protein …
Tacalyx is a biopharmaceutical company developing innovative therapeutics to target tumor-associated carbohydrate antigens (TACAs). To strengthen our team in Berlin-Adlershof, we …See details»
Tacalyx raises seed funding for antibodies for cancer …
Sep 25, 2019 Tacalyx secured access to licenses and the know-how from Max-Planck-Innovation GmbH to the underlying technology and related discoveries made by its scientific co-founders, Peter H. Seeberger, Director at the Max …See details»
Tacalyx Raises €7 Million in Seed Funding to Generate First in Class ...
Tacalyx, a biotech company focused on the discovery and development of novel anti-TACA (Tumor Associated Carbohydrate Antigens) cancer therapies, today announced that it has …See details»
More documents for Tacalyx GmbH - Life-Sciences-Europe.com
With its platform, Tacalyx has developed a pipeline of seven projects targeting both known and novel TACAs with high relevance for human malignancies. Dr. Peter Sondermann, CEO and …See details»
Tacalyx - Tech Stack, Apps, Patents & Trademarks - Crunchbase
Tacalyx is a biotech company focused on the discovery and development of novel anti-TACA. New. Resources. Advanced Search. Start Free Trial . Talk With Sales. Pricing. Log In. Log In. …See details»
Tacalyx • life science startup - HTGF
Sep 25, 2019 Tacalyx, a biotech company focused on the discovery and development of novel anti-TACA (Tumor Associated Carbohydrate Antigens) cancer therapies, today announced …See details»
Tacalyx - Contacts, Employees, Board Members, Advisors & Alumni
Tacalyx is a biotech company focused on the discovery and development of novel anti-TACA. New. Resources. Advanced Search. Start Free Trial . Talk With Sales. Pricing. Log In. Log In. …See details»
Tacalyx Company Information - Funding, Investors, and More
Track over 71,000 companies. Discover Fast-growing Global startups. Seedtable uses technology and people to track over 71,000 companies to help you find the right ones to partner with.See details»
€7 Million to Generate First in Class Anti-TACA Antibodies for …
Sep 26, 2019 Tacalyx secured access to licenses and the know-how from Max-Planck-Innovation GmbH to the underlying technology and related discoveries made by its scientific …See details»
Over €14 M to Advance Development of Tacalyx’s Cancer
Jun 28, 2024 Tacalyx, a privately held biotech company focused on developing novel anti-TACA (Tumor Associated Carbohydrate Antigens) cancer therapies, announces the extension of its …See details»
Tacalyx - EU-Startups
Articles about Tacalyx: June 14, 2024 Weekly funding round-up! All of the European startup funding rounds we tracked this week (June 10 – 14) September 25, 2019 Berlin-based biotech …See details»
Tacalyx Will Develop Carbohydrate-Targeting Cancer Treatments
Sep 25, 2019 The German startup Tacalyx has raised €7M in a seed round to fund the preclinical development of first-in-class carbohydrate-targeting antibody drugs for the …See details»